Checkpoint Inhibitors in Malignant Pleural Mesothelioma
0 vistas
• 07/02/23
0
0
Empotrar
administrator
Suscriptores
Mark Socinski, MD; Mary Jo Fidler, MD; Roy Herbst, MD, PhD; Geoffrey Oxnard, MD; and Naiyer Rizvi, MD discuss the potential for checkpoint inhibitors, such as pembrolizumab, for malignant mesothelioma. Also discussed is the importance of trials that can be done in the community setting.
Mostrar más
Comentarios de Facebook
SORT BY-
Top Comentarios
-
Últimos comentarios